Drug Approval | October 07, 2023
Lupin receives tentative approval from USFDA for Tolvaptan Tablets
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
New Board of Directors and management team at Suven Pharma also appointed
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
The first phase of the hospital with 225 beds built over 1.75 lakh square feet will be commissioned in the next 12 months
Lupin has been exclusively marketing these brands in the Indian market since July 2021
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Subscribe To Our Newsletter & Stay Updated
